Rhythm Biosciences Limited
David Atkins is an accomplished executive in the life sciences and healthcare sectors, currently serving as the Chief Executive Officer at Rhythm Biosciences Limited and as an Advisor at Digistain® and COSMIC. Previously, David held leadership positions including CEO at Congenica, where innovative AI techniques for genomic data interpretation were developed, and CEO of Synevo at Medicover, overseeing a vast network of diagnostic laboratories. David's extensive experience in international markets includes roles as Vice President at Johnson & Johnson, managing various businesses in medical devices, diagnostics, and molecular diagnostics. With an educational background that includes an MBA from Columbia Business School and a PhD in Molecular Virology from the John Innes Institute, David has published over 30 articles in prestigious journals and is recognized for their contributions to advancing healthcare technology.
This person is not in any teams
Rhythm Biosciences Limited
Rhythm Biosciences is an innovative Australian, publicly listed medical diagnostics company, with a focus on delivering simple, affordable blood tests for the accurate detection of cancers, providing physicians with accurate and reliable diagnostic tools. Early detection is critical to improving patient outcomes and reducing the global burden of cancer. ColoSTAT®, Rhythm Bioscience’s first simple blood-based cancer test, designed for the early detection of colorectal cancer, has been developed initially as an alternative screening test for individuals unable to or are unwilling to use currently available screening modalities. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.